<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The presence and severity of cerebrovascular pathological findings have been shown to increase the risk and stage of <z:hpo ids='HP_0001268'>cognitive decline</z:hpo> observed in <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Thus, the modification of vascular risk factors seems useful to reduce the risk of <z:hpo ids='HP_0000726'>dementia</z:hpo> regardless of type </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">Hyperhomocysteinemia</z:e> has long been known as a major independent risk factor for vascular dysfunction </plain></SENT>
<SENT sid="3" pm="."><plain>In this study, we evaluated the relationships between plasma <z:chebi fb="0" ids="17230">homocysteine</z:chebi> levels and genetic risk factors for <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e>, i.e., the presence of gene variants for <z:chebi fb="0" ids="25297">methylenetetrahydrofolate</z:chebi> reductase (MTHFR) and endothelial nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase (eNOS) in patients with <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Genotyping for MTHFR C677T and eNOS 894G &gt; T polymorphisms was carried out in 69 patients with probable diagnosis of AD and anamnestic mild <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo>, matched for age and gender with 69 healthy volunteers </plain></SENT>
<SENT sid="5" pm="."><plain>Patients with MTHFR TT677 genotype showed higher plasma <z:chebi fb="0" ids="17230">Hcy</z:chebi> levels than controls, even after adjustment for <z:chebi fb="3" ids="37445">folate</z:chebi> levels (P &lt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>Moreover, <z:chebi fb="0" ids="17230">Hcy</z:chebi> plasma levels were higher in cases than controls for any given eNOS genotype </plain></SENT>
<SENT sid="7" pm="."><plain>In particular, the presence of eNOS TT894 genotype in patients with <z:hpo ids='HP_0001268'>cognitive decline</z:hpo> resulted significantly associated with increased plasma <z:chebi fb="0" ids="17230">Hcy</z:chebi> levels when compared with controls having the same genotype or patients having other eNOS genotypes (P = 0.02) </plain></SENT>
<SENT sid="8" pm="."><plain>These data suggest that both MTHFR C677T and eNOS G894T variants should be regarded as genetic risk factors for <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e> in patients with <z:hpo ids='HP_0001268'>cognitive decline</z:hpo> </plain></SENT>
</text></document>